clinical trial · NCT02709512
Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
MesotheliomaADI-PEG 20 plus Pem PlatinumPlacebo plus Pem Platinum
brief summary
This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with malignant pleural mesothelioma. Malignant pleural mesothelioma have been found to require arginine, an amino acid. Thus the hypothesis is that by restricting arginine with ADI-PEG 20, the malignant pleural mesothelioma cells will starve and die.
started
Aug 1, 2017
primary completion
Aug 15, 2022
completion
Aug 15, 2022
last updated
Oct 4, 2023
official title
Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesotheliomato Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol